Clinical trial
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases
NCT04603807 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 30, 2021
- Completion date
- January 29, 2028
- Enrollment
- 217 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.